The latest price target for Ovid Therapeutics (NASDAQ:OVID) was reported by Oppenheimer on January 29, 2025. The analyst firm set a price target for $4.00 expecting OVID to rise to within 12 months (a possible 474.22% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Ovid Therapeutics (NASDAQ:OVID) was provided by Oppenheimer, and Ovid Therapeutics upgraded their outperform rating.

The last upgrade for Ovid Therapeutics Inc happened on January 29, 2025 when Oppenheimer raised their price target to $4. Oppenheimer previously had a perform for Ovid Therapeutics Inc.

There is no last downgrade for Ovid Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ovid Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ovid Therapeutics was filed on January 29, 2025 so you should expect the next rating to be made available sometime around January 29, 2026.

While ratings are subjective and will change, the latest Ovid Therapeutics (OVID) rating was a upgraded with a price target of $0.00 to $4.00. The current price Ovid Therapeutics (OVID) is trading at is $0.70, which is within the analyst’s predicted range.